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Abstract 
 
The use of polymers to enhance the delivery of vaccines is a growing area of research. 
Microparticles formed from polysaccharides can be formulated into vaccines by encapsulating a 
protein target (an antigen) and an immune danger signal (an adjuvant).  The adjuvant is needed 
since most synthesized or subunit vaccines lack the immunologic potency that the entire 
pathogen would stimulate. Immunostimulatory polymers such as Inulin obtained from dahlia 
root could be used in place of a separate adjuvant.  Inulin can be used as a base material to form 
chemically-modified polymers, such as acetalated (Ace) or trimethylsilyl (TMS) Inulin. To this 
end, the degradation of chemically modified Inulin microparticles of varying reaction times and 
modifications was tested at pH 5 and 7.4 using a spectrophotometer. The results showed a much 
slower release in extracellular conditions (pH 7.4) with a burst release at pH 5, corresponding to 
the acidity of the phagosome of phagocytic cells, which are the gatekeepers to a vaccine-
mediated immune response in vivo. Additionally, the immunostimulatory effect of Inulin 
microparticles was evaluated using a TNF-α ELISA and the toxicity was evaluated using an 
MTT assay. Macrophages were incubated with five different concentrations (1000, 500, 250, 
100, 50 µg/ml) of various types of Inulin microparticles (20 min Ace-Inulin, 24 hr Ace-Inulin, 
TMS-Inulin). Results show that the inulin microparticles are biocompatible and display a dose-
dependent increase in TNF-α production. Currently, groups of inulin microparticles loaded with 
ova-albumin (a sample antigen) are being tested in vivo. Blood samples are being withdrawn 
from mice every 2 weeks, with a final sample at the end of six weeks. These samples will be 
tested using antibody titers, flow cytometry, and antigen recall. 
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Introduction 
 
Vaccination aims to generate a strong immune response against a selected antigen to 
provide long-lasting protection against infection.
1
 Subunit vaccines (e.g. protein-based) offer 
numerous advantages over attenuated and heat-inactivated vaccines. Attenuated (live) viruses 
cannot be broadly applied due to safety risk associated with many diseases. Heat inactivated 
vaccines are safer but lack efficacy in generating a strong immune response. Subunit vaccines 
are considered to be a safer alternative to live or attenuated vaccine formulations because they 
can establish protective immunity, yet lack the molecular machinery to cause an infection.
2
  
 Currently, aluminum salts are the most commonly used vaccine adjuvants in FDA-
approved vaccines. However, alum salts have been shown to induce allergenicity
3
, form 
granulomas at injection sites
4
, and only stimulate humoral responses
5,6
.  The optimal vaccine 
should activate both the humoral and cellular arms of adaptive immunity.
7 
Additionally, alum-
adjuvanted vaccines have been shown to lose potency upon lyophilization, which could create an 
issue with long-term storage of the formulation.
8
  
 An increasing amount of research has investigated the use of polymers to improve 
delivery of vaccines. Microparticles fabricated from FDA-approved polymeric biomaterials 
including α-hydroxy acids such as poly(lactic-co-glycolic) acid (PLGA) are used broadly. 
However, PLGA  has a slow degradation rate that is not ideal for delivery of antigenic payloads.
9
 
Additionally, the pH inside PLGA microparticles is acidic and provides an uncontrolled pH 
environment which can be an issue for antigen stability.
10
 For use in drug delivery and controlled 
release applications,
 
polymers sensitive to external stimuli such as magnetic fields, temperature, 
electric field and pH have been developed.
 
An important channel to achieve controlled release 
2 
 
involves using pH-sensitive polymers to fabricate microparticles and nanoparticles that capitalize 
on natural pH differences in vivo.
11
 pH-sensitive polymers have been used to target tumors
12,13
, 
facilitate escape from endolysosomal pathways
14
, and for uptake in the GI tract
15
. A pH-sensitive 
carrier allows for protein to be expediently delivered to antigen presentation systems due to the 
pH gradient in the endocytic pathway.
16, 17
 
 
Acetalated polymers have been shown to have pH-sensitive characteristics ideal for 
delivery of vaccine elements to immune cells.
18 
The degradation rate of acetalated dextran is 
easily tunable through the reaction time used to synthesize the polymer.
19
 Additionally, silylated 
polymers are a recently developed biodegradable polymer that have many of the same features as 
acetalated polymers.
20
 These polymers can be easily formed into microparticles using standard 
emulsion techniques since they become soluble in organic solvents.
 
Microparticles produced 
from polysaccharides can form vaccines by encapsulating a protein target (an antigen) and an 
immune danger signal (an adjuvant).  The adjuvant is often needed since most synthesized or 
subunit vaccines lack the immunologic potency that the entire pathogen would have stimulated.
21
 
Immunostimulatory polymers such as inulin obtained from dahlia root can act as the antigen 
delivery vehicle and could be used in place of including an additional adjuvant drug.  
To improve long-term storage of vaccine formulations, plant polysaccharides such as 
inulin can be used to prevent the degradation of proteins during lyophilization and storage.
22
 
Inulin is a biocompatible polymer used in the food industry
23
 and has been used clinically to 
measure renal function.
24
 Specific isoforms of inulin have been shown to activate the alternative 
complement pathway.
25 
Inulin-based adjuvants have successfully been tested in multiple animal 
models in combination with such antigens such as diphtheria, tetanus toxoid and hepatitis B.
1 
Inulin-derived adjuvants have also been shown to promote both Th1 and Th2 immune responses 
3 
 
in vivo.
26
 Inulin is an optimal adjuvant due to its biocompatibility, ability to promote both a 
cellular and humoral immune responses, and its cryoprotectant properties. 
This study aims to use an immunostimulatory polymer (inulin) to produce a more 
effective vaccine carrier that does not require the addition of a separate adjuvant. Inulin has been 
shown to be biocompatible and is commonly used in food and clinical settings. Chemical 
modifications of the inulin allow for easy fabrication of delivery vehicles with pH-sensitive 
properties optimal for vaccine delivery. Inulin also serves as a cryoprotectant and prevents 
degradation of protein.
22
 Additionally, inulin microparticles deliver antigens in particulate form 
which has been shown to be more immunogenic than the soluble form and to result in increased 
antigen uptake.
27,28
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Materials and Methods 
Materials.  
All materials were purchased from Sigma-Aldrich (St. Louis, MO) and used as received 
unless otherwise noted. 
Acetalated Polymer Synthesis 
Ace-Inulin (Ace-IN) was reacted in a similar method as used by Kauffman et al.
29
 
Briefly, lyophilized inulin (0.936 g, MW = 5,000) and pyridinium p-toluenesulfonate (0.0617 
mmol) were dissolved in anhydrous dimethyl sulfoxide (DMSO, 10 mL) and then reacted with 2-
ethoxypropene (37 mmol, Waterstone, Carmel, IN) under nitrogen gas.  For longer reaction 
times, chloroform (4 mL) was added to the reaction mixture after one hour. The reaction was 
quenched with triethylamine (TEA, 1 mL) at set timepoints (20 min, 24 hr, 72 hr). The product 
was then precipitated in basic water (0.02% v/v triethylamine in water, pH 9), isolated using 
vacuum filtration, and lyophilized. The polymer was further purified by dissolving in ethanol 
(200 proof) and centrifuging (5 min, 10,000 × g, Thermo Legend Micro 21). The supernatant 
was precipitated again in basic water, filtered, and lyophilized to yield Ace-IN polymer (1 g), a 
white powder. 
TMS-IN Polymer Synthesis 
Inulin (0.5 g) was dissolved in anhydrous DMSO (5 mL).  Triethylamine (1.2 g, 23.6 
mmol / gram inulin) was added dropwise.  The silylation of the inulin was performed by 
dropwise addition of the TMS-Cl (1.2 g, 22.4 mmol / gram Inulin).  The reaction mixture was 
stirred at room temperature under nitrogen gas.  After 30 min of reaction, 5 mL anhydrous 
chloroform was added, and the reaction was allowed to proceed for two more hours.  Following 
the 2.5 hr, the reaction was quenched by dilution with 200 mL chloroform.  The organic layer 
5 
 
was washed with saturated sodium bicarbonate solution followed by deionized water, dried over 
anhydrous sodium sulfate, and TMS-IN was collected as a white solid after lyophilization. 
Particle Synthesis 
Ace-IN OVA-loaded microparticles were prepared using a double-emulsion technique 
(water/oil/water) as previously described with Ace-DEX.
10 
Briefly, a stock solution of ovalbumin 
(OVA) in PBS (200 μL) was prepared. 100 mg of Ace-IN was dissolved in dichloromethane 
(DCM, 1 mL) and added to the OVA solution. This two-phase mixture was then homogenized 
for 30s (IKA-25 Ultra Turrax Homogenizer, S25N-18G head, 18,000 RPM). 12 mL of 3% poly 
(vinyl alcohol) (PVA) in PBS (12 mL) solution was then added to the emulsion formed and 
homogenized using the same settings. The resulting double emulsion was immediately poured 
into a spinning solution of 0.3% PVA in PBS (40 mL). After two hours of spinning to evaporate 
the solvent and allow for particle hardening, the mixture was centrifuged (10 min, 14,000 × g). 
The supernatant was discarded, and the resulting sediment was washed with basic water (pH 9) 
and centrifuged under the same conditions several times in order to remove excess PVA. Finally, 
the microparticles were suspended in basic water (pH 9) and lyophilized for two days to yield 
Ace-IN microparticles, a white powder. 
 Acetalated Dextran (Ace-DEX) microparticles were prepared with the same procedure as 
described above, except Ace-DEX was used in place of Ace-IN. This Ace-DEX polymer (MW = 
71k) was synthesized as previously described in Kauﬀman et al.29TMS-IN microparticles were 
also prepared with the same procedure, except TMS-IN polymer was used in place of Ace-DEX. 
Empty Ace-IN and TMS-IN Particles that did not contain protein were made in the same manner 
as the double-emulsion particles omitting the first emulsion with the OVA solution.  
6 
 
Particle Degradation 
Empty Ace-IN and TMS-IN particles were suspended in triplicate at a concentration of 3 
mg/mL in either a sodium acetate buffer (pH 5.0) or PBS (pH 7.4) and incubated at 37 °C on a 
shaker plate at 200 RPM. At various timepoints (0 to 336 hours) samples were analyzed using a 
spectrophotometer (600 nm). A standard curve was created with a range in concentrations of 
Inulin microparticles in PBS to determine percent degradation of the particles.   
Quantification of Encapsulated OVA 
Blank and OVA-loaded particles were prepared at 3 mg/mL in 1% (w/v) Sodium 
Dodecyl Sulfate (SDS) in 0.3 M sodium acetate buffer (pH 5.0).  The solutions were incubated at 
90 C until complete degradation of the particles was observed.  A standard curve using free OVA 
was treated the same way.  150 uL of the samples/standards were reacted with 50 uL of 3 mg 
fluorescamine / mL in DMSO for 15 min.  The fluorescence was read at Ex:390 / Em:470 nm. 
Scanning Electron Microscopy 
Particle suspensions were prepared at 10mg/mL in basic water (pH 9.0), and a 50 uL drop was 
put on an aluminum pin stub specimen mount (Ted Pella, Inc., Redding, CA) and allowed to air 
dry.  The sample was sputter-coated with AuPd for 90 sec using a Sputter Coater 108 
(Cressington Scientific Instruments, Watford, England).  Images were acquired using a Nova 
NanoSEM 400 scanning electron microscope (Field Emission, Inc., Hillsboro, OR). 
Endotoxin Levels 
Particle suspensions were prepared at 1mg/mL in endotoxin free water and incubated overnight 
at 4 C.  The amount of endotoxin was measured following the manufacturer's instructions using a 
Pierce LAL Chromogenic Endotoxin Quantification Kit (Thermo Fisher Scientific, Rockford, 
IL). 
7 
 
Cell Preparation  
Macrophages (RAW 264.7; ATCC, Manassas, VA) were grown and maintained according to the 
manufacturer’s guidelines. Media was made with fetal bovine serum (50 mL; Hyclone, 
Pittsburgh, PA), penicillin-streptomycin (5 mL; Fischer, Pittsburgh, PA), and Dulbecco’s 
Modified Eagle’s Medium (450 mL; Fischer, Pittsburgh, PA). Cells were maintained at 100% 
relative humidity, 37 °C, and 5% CO2. Macrophages were seeded at a concentration of 2 × 10
5
 
cells/mL in a 96-well plate. After 4 hours, the media in each well was replaced with treatment 
media containing blank Ace-IN and TMS-IN microparticles at concentrations ranging from 100 
to 1000 µg/mL. Controls included three wells with only media, three wells with untreated cells, 
and three wells with 10 ug/ml LPS as a positive control. Cells were then incubated for 48 hours. 
Cell Viability analysis. 
After 48 hours of treatment, the MTT assay was performed to determine cell viability. Media 
was removed from wells and replaced with 150 uL of fresh media and 20 μL of 3-(4,5 
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) dissolved in medium (5 mg/mL) 
was added. The plate was incubated for 3 hours until purple formazan crystals formed. Then, the 
supernatants were removed and crystals were dissolved in isopropanol (200 μL). The plate was 
analyzed with a plate reader at an absorbance of 560 nm, and the background absorbance at 670 
nm was subtracted. The net absorbance scaled by the net absorbance of the untreated cells 
(100%) corresponds to the cell viability.  
 
Cytokine Analysis. 
 
After 48 hours of treatment to the cells, supernatants from each well were removed and frozen at 
-80ºC. A Mouse TNF-α ELISA Ready-SET-Go!® kit (Affymetrix, Santa Clara, CA) was used to 
assess TNF-α Alpha levels in the samples. A 10 μL aliquot of each sample was pipetted into a 96 
8 
 
well plate for cytokine analysis. This and a Mouse IL-6 Ready-SET-Go!® kit (Affymetrix, Santa 
Clara, CA) ELISA were performed following the manufacturer’s directions.  
 
Nitrite Analysis 
Nitric oxide production by the macrophages was measured using a Greiss Assay. After 48 hours, 
the supernatants from each well were removed and centrifuged (14,000 × g, 4 °C, 10 min), and 
50 μL of the resulting supernatant was withdrawn and pipetted into a 96 well plate. Standard 
nitrite concentrations were prepared and the Greiss reagents (Promega, Madison, WI) were 
added following the manufacturer’s directions. The absorbance was measured at 540 nm and 
compared with the standard curve to determine nitrite concentration. 
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Results and Discussion 
Physical Characterization of Microparticles 
Ace-IN and TMS-IN polymer was synthesized using the reaction schemes shown in 
Figure 1. Microparticles were synthesized from three reaction times for the Ace-IN polymer (20 
min, 24 hour, 72 hour) and for the TMS-IN as seen in Figure 2. The microparticles were fairly 
polydisperse with diameters ranging from a few hundred nanometers to a couple microns. In 
order to ensure there was no contamination that could lead to false positives, particles were 
tested for endotoxin using a quantitative LAL Endotoxin test which resulted in a negligible 
amount of endotoxin being detected. 
 
Figure 1: Reaction schemes used to synthesize: (A) Acetalated Inulin and (B) Trimethylsilyl 
Inulin 
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Figure 2: Scanning electron micrographs of blank microparticles fabricated by an oil/water 
emulsion: (A) Ace-IN 20min, (B) Ace-IN 24hr, (C) Ace-IN 72hr, and (D) TMS-IN.  Scale bars = 
5 µm. 
 
Microparticle Degradation, Encapsulation Efficiency of Antigen, and Antigen Release 
Reaction time has been shown to control the degradation rate of Ace-DEX particles.
29
 It 
was expected that Ace-IN would have a similar degradation to acetalated dextran due to its acetal 
groups. The degradation of Ace-IN and TMS-IN microparticles synthesized using the emulsion 
method was analyzed in pH 5.0 and pH 7.4 buffers. The pH 5.0 buffer was used to model the 
physiological pH of phagosomal conditions of antigen presenting cells (e.g. macrophages) as 
well as sites of inflammation. Acid sensitivity is advantageous for a microparticle carrier since it 
allows for the payload to be localized to acidic sites (e.g. phagosomes) instead of physiological 
pH-neutral sites making delivery more efficient and reducing potential side effects intracellular. 
11 
 
Figure 3 shows the degradation of 20 minute Ace-IN particles, 24 hour Ace-IN particles, and 
TMS-IN particles.  
 
Figure 3: Degradation of blank inulin microparticles at 200 RPM, 37 ºC in (A) pH 5 Sodium 
Acetate buffer and (B) pH 7.4 Phosphate-Buffered Saline buffer performed at 200 rpm, 37ºC, 
n=3. 
 
 
As expected, the lower reaction time Ace-IN degraded faster than the 24 hour Ace-IN particles, 
which shows degradation tunability based on the reaction time. Furthermore, TMS-IN particles 
12 
 
degraded slower than the Ace-IN particles, which implies an ability to further tune the 
degradation based on the chemical modification. All of the particles show a more triggered 
degradation in the pH 5.0 buffer as compared to being more stable at pH 7.4. 
Double-emulsion microparticles loaded with OVA were prepared to investigate antigen 
release from the Ace-IN microparticles. The release is shown below in Figure 4. pH 5.5 was used  
instead of pH 5.0 to avoid OVA’s isoelectric point and assure that it would remain in solution. A 
burst release was observed at the pH 5.5 and a slower release at pH 7.4 demonstrating the pH 
sensitivity and ability for the microparticles to release an antigen in a tunable fashion. This 
demonstrates the ability of particles to rapidly deliver antigen at a lower pH which has been 
shown to correspond with greater antigen presentation.
30
  
 
 
 
Figure 4: Release of ovalbumin (OVA) from Ace-IN: 72hr microparticles at pH 5.5, and pH 7.4 
performed at 200 rpm, 37ºC, n=3. 
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After determining the degradation profile of the inulin microparticles, the ability of 
microparticles to encapsulate a model antigen (OVA) was tested. Issues arose with the 
encapsulation efficiency in TMS-IN, and therefore various polymer blends of Ace-DEX and 
TMS-IN were used to alleviate this problem. The encapsulation results can be seen in Table 1. 
With an increasing percentage of Ace-DEX, a non-immunostimulatory polymer, in the blend the 
encapsulation efficiency increased demonstrating tunability based on the amount of ovalbumin 
loading desired. 
Table 1: Encapsulation Efficiency of OVA in TMS-IN/Ace-DEX blended microparticles (MPs). 
Particle Type Encapsulation 
Efficiency (%) 
100% TMS-IN  4.28 ± 1.58 
75% TMS-IN/25% Ace-DEX 14.02  ± 1.58 
50% TMS-IN/50% Ace-DEX 27.04 ± 0.72 
100% Ace-DEX 61.59 ± 0.86 
 
 
Immune Characterization of Microparticles 
 
Empty particles were tested for their cytotoxicity using the MTT assay and ability to 
induce an immune response using a tumor necrosis factor alpha (TNF-α) ELISA. TNF-α is a pro-
inflammatory cytokine produced in response to infectious agents and has been shown to play an 
important role in immune and inflammatory activities.
31
 Previously, it has been shown that inulin 
is immunostimulatory, so it was expected for the particles to result in cytokine release.
24
As seen 
in Figure 5, there was a significant TNF- α release with the Ace-IN particles. It can also be seen 
that there is a trend, with increasing reaction time resulting in a smaller TNF-α release. This 
demonstrates potential tunability for the degree of immunogenicity based on the reaction time of 
the polymer. One potential mechanism explaining this is a rapid degradation for lower reaction 
time acetalated inulin (as can be seen earlier in Figure 3) resulting in expedient delivery of inulin 
14 
 
to phagosomes for greater antigen presentation.
30
Additionally, there was a relatively high TNF-α 
released with treatment of TMS-IN particles. Viability for all the particles was above 80 percent 
for concentrations equal to or below 250 ug/ml, indicating that the particles are relatively not 
cytotoxic. 
 
 
 
 
Figure 5: (A) Viability of RAW 264.7 macrophages determined by an MTT assay after 48 hours 
of treatment  (B) Tumor necrosis factor alpha (TNF-α) levels produced by RAW 264.7 
macrophages treated for 48 hours with blank microparticles. 10 µg/mL of lipopolysaccharide 
(LPS) was incubated for a reduced amount of time to act as a positive control.  Data are 
displayed as mean ± standard deviation, n=3. 
 
In Figure 6, the TNF-α production from free Inulin at the same concentrations as the 
particulate form of inulin is displayed. With free inulin, there was no TNF-α release seen for any 
of the concentrations. This indicates that especially when in microparticle form, inulin results in 
a Th1 immune response. This is consistent with the results that have been obtained previously by 
Kumar et al. using soluble inulin microparticles.
32
It can also be seen from the MTT results that 
free inulin, a degradation byproduct of the particles, is biocompatible. 
15 
 
 
 
Figure 6: (A) Viability of RAW 264.7 macrophages determined by an MTT assay after 48 hours 
of treatment.  Data are presented as relative to untreated cells and are displayed as mean ± 
standard deviation.  (B) Tumor necrosis factor alpha (TNF-α) levels produced by RAW 264.7 
macrophages treated for 48 hours with free inulin.  10 µg/mL of lipopolysaccharide (LPS) was 
incubated for a reduced amount of time to act as a positive control.  Data are displayed as mean ± 
standard deviation, n=3. 
Additional experiments assessing the ability for inulin to induce a Th1 response were 
performed including tests for IL-6 and nitric oxide, other inflammatory markers, but no response 
was detected as can be seen in Figures S-1, and S-2. Ace-IN blended with Ace-DEX 
microparticles were also tested for TNF-alpha emission as seen in Figure S-3. 
In Vivo Experiments 
 
After characterizing the physical and immune-modulating properties of inulin 
microparticles, microparticle degradation, and ability to encapsulate sample antigen, in vivo 
experiments were planned. In vivo experiments are ongoing and will characterize the humoral 
and cellular immune responses to the particles with anti-OVA antibody titers, flow cytometry 
and antigen recall. The encapsulation efficiency of the particles used in the in vivo experiment is 
displayed in Table 2. 
 
16 
 
Table 2: Encapsulation Efficiency of microparticles (MPs) used for in vivo experiment. 
Particle Type Encapsulation 
Efficiency (%) 
24 hr Ace-IN 24.46  ± 0.66 
50% TMS-In/50% Ace-DEX 27.04 ± 0.72 
Ace-DEX 61.59 ± 0.86 
 
The experimental groups chosen for the in vivo experiment are in Table 3. Delivery of OVA-
loaded particles and free OVA in combination with blank particles were chosen with the 
appropriate controls. 
Table 3: In vivo experimental groups 
Group 
1 PBS 
2 Blank Ace:IN:24hr MPs 
3 Blank TMS:IN MPs 
4 Free OVA 
5 Free OVA + Alum 
6 Free OVA + Ace:IN:24hr MPs 
7 Free OVA + TMS:IN MPs 
8 Ace:IN:24hr/OVA MPs 
9 TMS:IN/OVA MPs 
10 Ace-DEX:71k:50min/OVA MPs 
 
The experimental plan for the in vivo experiment is displayed in Figure 7.  Mice will be injected 
on Day 0 with a booster injection on Day 14 and will have blood samples taken every 2 weeks 
for 6 weeks total.  Following euthanasia, the spleens will be excised and splenocytes recovered 
to determine the cell populations (e.g. CD8+) and ability of the splenocytes to recall the OVA 
antigen. Additionally, anti-OVA antibody titers will be analyzed to quantify the immune cell 
activation. 
17 
 
 
Figure 7: Schedule for in vivo experiment 
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Conclusions 
 
It can be concluded that chemically-modified inulin has numerous properties that are 
optimal for a vaccine carrier. Both TMS-IN and Ace-IN show pH-sensitive characteristics 
beneficial for delivery of vaccines to phagocytic cells. Additionally, both types of microparticles 
are relatively biocompatible and immunostimulatory, causing a dose-dependent increase in TNF-
alpha production. Due to the immunostimulatory effect of Inulin, these microparticles when 
formulated into a vaccine may not require a separate adjuvant drug. Tunability in degradation 
and immunogenicity has been demonstrated with Ace-IN particles based on the reaction time of 
the polymer synthesis. An increase in antigen loading can be achieved with TMS-IN by utilizing 
polymer blends containing Ace-DEX, another biocompatible polymer. Once results are obtained 
from the in vivo experiments, the effect of a chemically-modified inulin as a potential vaccine 
carrier can be further evaluated as part of a vaccine formulation for a specific disease. 
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Supplementary Figures 
 
 
 
Figure S.1.:  Interleukin-6 (IL-6) levels produced by RAW 264.7 macrophages treated for 48 
hours with blank microparticles.  10 µg/mL of lipopolysaccharide (LPS) was incubated for a 
reduced amount of time to act as a positive control.  Data are displayed as mean ± standard 
deviation. 
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Figure S.2: Nitric Oxide (NO) levels produced by RAW 264.7 macrophages treated for 48 hours 
with blank microparticles.  10 µg/mL of lipopolysaccharide (LPS) was incubated for a reduced 
amount of time to act as a positive control. 
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Figure S.3: Tumor necrosis factor alpha (TNF-α) levels produced by RAW 264.7 macrophages 
treated for 48 hours with blank microparticles blended with Ace-DEX:71k:20min.  10 µg/mL of 
lipopolysaccharide (LPS) was incubated for a reduced amount of time to act as a positive control. 
